|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the EYE 8-K filed Feb 25, 2009. FOR ITS 7 1/2% SENIOR SUBORDINATED NOTES DUE 2017 SANTA ANA, Calif., Feb. 25, 2009 Advanced Medical Optics, Inc. (AMO) [NYSE: EYE] announced today the expiration of the tender offer and consent solicitation (the Offer) for its outstanding 7 1/2% Senior Subordinated Notes due 2017 (the Notes) (CUSIP No. 00763MAN8, ISIN No. US00763MAN83). The Offer expired at midnight EST on Tuesday, Feb. 24, 2009, (the Expiration Time). As of the Expiration Time, $248,250,000 aggregate principal amount of Notes, representing approximately 99.3% of the aggregate principal amount of Notes outstanding, had been validly tendered pursuant to the Offer and not withdrawn. AMO accepted for payment, and will pay for, $248,250,000 aggregate principal amount of Notes today (the Payment Date). Holders who validly tendered their Notes and delivered their related consents prior to the Expiration Time received the Total Consideration of $1,155.00 for each $1,000 principal amount of Notes validly tendered and accepted for payment. In addition, all holders whose Notes were accepted for payment received accrued and unpaid interest up to, but not including, the Payment Date. In addition, pursuant to the Offer, AMO received consents from holders sufficient to approve the proposed amendments to the indenture governing the Notes. As a result, AMO and the trustee will enter into a supplemental indenture containing the proposed amendments to such indenture. This press release is for informational purposes only and is not an offer to purchase, a solicitation of an offer to sell or a solicitation of a consent with respect to any of the Notes. The tender offer and the consent solicitation were only made pursuant to the tender offer and the consent solicitation documents, including the Offer to Purchase that AMO distributed to holders of Notes. The tender offer and the consent solicitation were not made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.
This excerpt taken from the EYE 10-K filed Feb 24, 2009. 7 1/2% Senior Subordinated Notes Due 2017 In April 2007, the Company issued $250 million of 7 1/2% Notes due May 1, 2017. Interest on the 7 1/2% Notes is payable on May 1 and November 1 of each year, commencing on November 1, 2007. The 7 1/2% Notes are redeemable at the option of the Company, in whole or in part, at any time on or after May 1, 2012 at various redemption prices, together with accrued and unpaid interest and additional interest, if any, to the redemption date. In addition, at any time on or before May 1, 2010, the Company may, at its option and subject to certain requirements, use the cash proceeds from one or more qualified equity offerings by the Company to redeem up to 35% of the aggregate principal amount of the 7 1/2% Notes issued under the Indenture at a redemption price equal to 107.5% of the principal amount, together with accrued and unpaid interest, if any, thereon to the redemption date. This excerpt taken from the EYE 10-K filed Mar 3, 2008. 7 1/2% Senior Subordinated Notes Due 2017 (7 1/2% Notes) In April 2007, the Company issued $250 million of 7 1 /2% Senior Subordinated Notes due May 1, 2017. Interest on the 7 1/2% Notes is payable on May 1 and November 1 of each year, commencing on November 1, 2007. The 7 1/2% Notes are redeemable at the option of the Company, in whole or in part, at any time on or after May 1, 2012 at various redemption prices, together with accrued and unpaid interest and additional interest, if any, to the redemption date. In addition, at any time on or before May 1, 2010, the Company may, at its option and subject to certain requirements, use the cash proceeds from one or more qualified equity offerings by the Company to redeem up to 35% of the aggregate principal amount of the 7 1/2% Notes issued under the Indenture at a redemption price equal to 107.5% of the principal amount, together with accrued and unpaid interest, if any, thereon to the redemption date. | EXCERPTS ON THIS PAGE:
|
| |||||||